Recent in vitro studies reported that nitric oxide release and pulmonary vasorelaxation can be mediated by endothelial ␣ 2 -adrenoceptor activation. As norepinephrine (␣ 1 -,␣ 2 -, and ␤ 1 -adrenoceptor agonist) was found to induce pulmonary vasodilation in the ovine fetus, we hypothesized that ␣ 2 -adrenoceptors may modulate basal pulmonary vascular tone and mediate the vascular effect of norepinephrine during fetal life. To determine the role of ␣ 2 -adrenoceptors and the mechanisms of norepinephrine-mediated vasodilation in the fetal pulmonary circulation, we tested, in chronically prepared late-gestation fetal lambs, the hemodynamic response to 1) yohimbine (␣ 2 antagonist); 2) UK 14,304 (␣ 2 agonist) with and without L-nitro-arginine (nitric oxide synthase inhibitor); and 3) norepinephrine infusion with and without yohimbine. We found that yohimbine increased mean pulmonary artery pressure by 15% (p Ͻ 0.05), decreased pulmonary flow by 22% (p Ͻ 0.01), and increased pulmonary vascular resistance by 51% (p Ͻ 0.01). UK 14,304 increased pulmonary flow by 145% (p Ͻ 0.01) and decreased pulmonary vascular resistance by 58% (p Ͻ 0.01). L-Nitro-arginine abolished the UK 14,304-mediated pulmonary vasodilation. Norepinephrine (0.5 g·kg Ϫ1 ·min Ϫ1 ) increased both pulmonary flow by 61% (p Ͻ 0.01) and pulmonary arterial pressure by 13% (p Ͻ 0.01) and decreased pulmonary vascular resistance by 33% (p Ͻ 0.01). Yohimbine abolished the norepinephrine-induced pulmonary vasodilation. This study suggests that 1) a basal ␣ 2 -adrenoceptor activation-induced pulmonary vasodilation exists during fetal life; 2) the pulmonary vascular effects of ␣ 2 -adrenoceptor activation are related at least in part to nitric oxide production; and 3) the norepinephrine-mediated pulmonary vasodilation involves ␣ 2 -adrenoceptor activation. As a surge of norepinephrine exists at birth, we speculate that norepinephrine and endothelial ␣ 2 -adrenoceptor activation may play a significant role in pulmonary vasodilation at birth. High resistance and low blood flow characterize the fetal pulmonary circulation. PVR decreases dramatically during the normal transition from the fetal to neonatal circulation at birth. Three main factors contribute to the increase of Q p during this transition: ventilation of the lung (1), increased O 2 (2), and hemodynamic forces, such as increased shear stress (3). Vasoactive mediators released from the endothelium, such as NO, play a major role in the regulation of acute changes in vascular tone in the perinatal lung, and in many cases, modulate the pulmonary vascular response to these birth-related stimuli (4). Inhibition of NO synthesis can attenuate the postnatal adaptation of the pulmonary circulation (5). The vasodilator action of several substances, such as acetylcholine, bradykinin, or ADP, and shear stress are dependent, at least in part, on NO release (6). More recently, in vitro studies reported that NO release and pulmonary vasorelaxation can also be mediated by endothelial ␣ 2 -adrenoceptor activation (7-9). However, little is known about the role of ␣ 2 -adrenoceptors on the basal pulmonary vascular tone during fetal life and on the adaptation of the pulmonary circulation at birth.
High resistance and low blood flow characterize the fetal pulmonary circulation. PVR decreases dramatically during the normal transition from the fetal to neonatal circulation at birth. Three main factors contribute to the increase of Q p during this transition: ventilation of the lung (1), increased O 2 (2) , and hemodynamic forces, such as increased shear stress (3) . Vasoactive mediators released from the endothelium, such as NO, play a major role in the regulation of acute changes in vascular tone in the perinatal lung, and in many cases, modulate the pulmonary vascular response to these birth-related stimuli (4) . Inhibition of NO synthesis can attenuate the postnatal adaptation of the pulmonary circulation (5) . The vasodilator action of several substances, such as acetylcholine, bradykinin, or ADP, and shear stress are dependent, at least in part, on NO release (6) . More recently, in vitro studies reported that NO release and pulmonary vasorelaxation can also be mediated by endothelial ␣ 2 -adrenoceptor activation (7) (8) (9) . However, little is known about the role of ␣ 2 -adrenoceptors on the basal pulmonary vascular tone during fetal life and on the adaptation of the pulmonary circulation at birth.
Increase in plasma catecholamine concentration has been observed at the end of gestation, with the predominant circulating catecholamine being norepinephrine (10, 11) . Birth in-duces a marked surge in catecholamine secretion (12) . Increased catecholamines at delivery promote lung fluid reabsorption, surfactant release, and systemic circulatory adaptation (13, 14) . However, the effects on the pulmonary circulation are uncertain. Although norepinephrine is commonly known as a vasopressor agent, in vitro studies have shown that norepinephrine dilates some systemic (15) and pulmonary (16) vessels in newborn animals. We reported that norepinephrine infusion induces a potent NO-dependent pulmonary vasodilation in fetal lambs (17) . As ␣ 2 -adrenoceptor antagonists were found to inhibit norepinephrine-mediated relaxation of pulmonary (16, 18) or systemic arteries (15) , or enhance norepinephrine-mediated pulmonary vasoconstrictive response (8, 9) , norepinephrine-mediated pulmonary vasodilation may result from activation of endothelial ␣ 2 -adrenoceptors.
Accordingly, the main hypotheses tested in this study were that 1) ␣ 2 -adrenoceptors are involved in the control of basal pulmonary vascular tone during perinatal life; 2) the effects of ␣ 2 -adrenoceptors activation are related to NO production; and 3) the pulmonary vascular effects of norepinephrine are at least in part mediated by ␣ 2 -adrenoceptor activation. To test these hypotheses, we studied, in chronically prepared late-gestation fetal lambs, the hemodynamic response to 1) selective ␣ 2 -adrenoceptor activation, with and without NOS inhibition, and selective ␣ 2 -adrenoceptor blockade; and 2) norepinephrine associated with selective ␣ 2 -adrenoceptor blockade.
METHODS

Animal Preparation
All animal procedures and protocols used in this study were reviewed and approved by the French "Ministère de l'Agriculture, de la Pêche et de l'Alimentation" before the studies were conducted. Mixed-breed (Columbia-Rambouillet) pregnant ewes between 126 and 128 d gestation (term, 147 d) were fasted for 48 h before surgery. Ewes were sedated with i.v. pentobarbital sodium (total dose, 2-4 g) and anesthetized with 1% bupivacaine hydrochloride (4 mg) by lumbar puncture. Ewes were kept sedated but breathed spontaneously throughout the surgery. Under sterile conditions, the fetal lamb's left forelimb was delivered through a uterine incision. A skin incision was made under the left forelimb after local infiltration with lidocaine (2 mL, 1% solution). Polyvinyl catheters (20-gauge) were advanced into the ascending aorta and the superior vena cava after insertion in the axillary artery and vein. A left thoracotomy exposed the heart and great vessels. Catheters were inserted into the LPA (22-gauge), main pulmonary artery (20-gauge) , and left atrium (20-gauge) by direct puncture through pursestring sutures and secured as described (19) . An ultrasonic flow transducer (size 6; Transonic Systems, Ithaca, NY, U.S.A.), was placed around the LPA to measure blood flow. The uteroplacental circulation was kept intact, and the fetus was gently replaced in the uterus. An additional catheter was placed in the amniotic cavity to measure pressure. Amoxicillin (500 mg) was added to the amniotic cavity before closure of the hysterotomy. The flow transducer and catheters were exteriorized through a subcutaneous tunnel to an external flank pouch. Catheters were maintained by daily infusions of 2 mL of heparinized saline (10 U/mL). Catheter positions were verified at autopsy. Studies were performed after a minimum recovery time of 48 h. Estimated weight of the fetal lambs was 3000 g.
Physiologic Measurements
The flow transducer cable was connected to an internally calibrated flowmeter (T201; Transonic Systems), for continuous measurements of left Q p. The output filter of the flowmeter was set at 30 Hz. The absolute value of flow was determined from the mean of phasic blood flow signals (at least 30 cardiac cycles), with zero blood flow defined as the measured flow value immediately before the beginning of systole (20) . Main pulmonary artery, aortic, left atrial, and amniotic catheters were connected to blood pressure transducers (Merlin monitor, Hewlett-Packard, U.S.A.). Pressures were referenced to the amniotic cavity pressure. Calibration of the pressure transducers was performed with a mercury manometer. Heart rate was determined from the phasic Q p signal. PVR in the left lung was calculated as the difference between PAP and LAP divided by mean left Q p. Blood samples from the main pulmonary artery catheter were used for blood gas analysis and oxygen saturation measurements (OSM 3 hemoximeter and ABL 520, Radiometer, Copenhagen, Denmark).
Experimental Design
Five different experimental protocols were included in this study: 1) the effect of ␣ 2 -adrenoceptor blockade on basal pulmonary vascular tone; 2) pulmonary hemodynamic response to ␣ 2 -adrenoceptor activation; 3) pulmonary hemodynamic response to ␣ 2 -adrenoceptor activation after NOS inhibition; 4) pulmonary hemodynamic response to norepinephrine; and 5) effect of ␣ 2 -adrenoceptor blockade on the hemodynamic response to norepinephrine. Protocol 1. Effect of ␣ 2 -adrenoceptor blockade on basal pulmonary vascular tone. Saline (6 mL/h) was infused into the LPA for at least 30 min. Starting 30 min after stable baseline measurements, yohimbine was infused into the LPA at a rate of 0.75 mg/kg for 10 min, followed by a continuous infusion of 0.75 mg/kg for 110 min (6 mL/h). Preliminary tests showed that lower doses (0.1, 0.2, or 0.5 mg/kg) or bolus alone did not provide sustained ␣ 2 -adrenoceptor blockade. The LPA catheter was then infused with saline (6 mL/h) for 30 min.
Protocol 2. Pulmonary hemodynamic response to ␣ 2 -adrenoceptor activation. Saline (6 mL/h) was infused into the LPA for at least 30 min. Starting 30 min after stable baseline measurements, UK 14,304 was infused into the LPA at a rate of 0.8 mg/kg (6 mL/h) for 120 min. Preliminary tests showed that lower doses (0.2 and 0.4 mg/kg) did not induce major changes in PVR. Conversely, higher doses decreased AoP and caused severe acidosis. The LPA catheter was then infused with saline (6 mL/h) for 30 min.
Protocol 3. Pulmonary hemodynamic response to ␣ 2 -adrenoceptor activation after NOS inhibition. Protocol 2 was repeated after L-NA infusion. Saline (6 mL/h) was infused into the LPA for at least 30 min. Starting 30 min after stable 45 baseline measurements, L-NA (30 mg for 10 min) was infused into the LPA (from 30 min to 40 min). This dose was selected from past studies that have demonstrated effective blockade of NOS activity during acetylcholine-and flow-induced vasodilation for at least 4 h (5). Then the pulmonary artery catheter was flushed with normal saline at a constant rate of 6 mL/h during 20 min, before starting the UK 14,304 infusion (from 60 to 180 min).
Protocol 4. Pulmonary hemodynamic response to norepinephrine. Saline (6 mL/h) was infused into the venous catheter for at least 30 min. Starting 30 min after stable baseline measurements, norepinephrine was infused for 120 min into the venous catheter at a rate of 0.5 g·kg Ϫ1 ·min Ϫ1 (6 mL/h). The catheter was then infused with saline (6 mL/h) for 30 min.
Protocol 5. Effect of ␣ 2 -adrenoceptor blockade on the hemodynamic response to norepinephrine. Saline (6 mL/h) was infused into the LPA and into the venous catheter for at least 30 min. After 30 min of stable baseline measurements, yohimbine was infused into the LPA at a rate of 0.75 mg/kg for 10 min, followed by a continuous infusion of 0.75 mg/kg for 110 min (6 mL/h). Norepinephrine infusion (0.5 g·kg Ϫ1 ·min Ϫ1 for 120 min, 6 mL/h) was infused into the venous catheter and started 20 min after the beginning of yohimbine infusion. Both catheters were then infused with saline (6 mL/h) for 30 min.
Main PAP, LAP, mean AoP, amniotic pressure, left Q p, and heart rate were recorded at 10-min intervals in each protocol. PVR in the left lung was calculated.
Drug Preparation
Norepinephrine (Aguettant, Lyon, France), and yohimbine hydrochloride (Sigma Chemical Co, St Quentin Fallavier, France) were diluted in normal saline to a concentration of 15 g/mL, and 2 mg/mL, respectively. UK 14,304 (Sigma Chemical Co., St Quentin Fallavier, France) was diluted in 2 drops of DMSO, then further diluted in normal saline to a concentration of 360 g/mL. L-NA (30 mg) was dissolved in a few drops of 1 M HCl, and diluted in 1 mL of normal saline. NaOH was then used to titrate the pH to 7.40. All drugs except norepinephrine were infused in the LPA.
Data Analysis
The results are presented as mean Ϯ SD. The data were analyzed using repeated-measures and factorial ANOVA. Intergroup differences were analyzed with the Fisher's, Scheffé's, and Bonferroni/Dunn's least significant test (StatView for PC; Abacus Concepts, Berkeley, CA, U.S.A.). A p Ͻ 0.05 was considered as statistically significant. ; p Ͻ 0.01) during the study period (Fig. 2) . Mean LAP before infusion was 2 Ϯ 1 mm Hg and did not change during the study period. AoP, heart rate, and pulmonary arterial PO 2 did not change during the infusion (Table1).
RESULTS
Protocol
Protocol 3. Pulmonary hemodynamic response to ␣ 2 -adrenoceptor activation after NOS synthase inhibition. L-NA infusion did not significantly change mean PAP and Q p. However, mean PVR increased by 15% (from 0.54 Ϯ 0.06 to 0.63 Ϯ 0.09 mm Hg·min·mL Ϫ1 ; p Ͻ 0.01; n ϭ 5). After L-NA infusion, UK 14,304 infusion increased both mean PAP and mean PVR by 29% and 19%, respectively (Fig. 3) . Q p did not change during UK 14,304 infusion (Fig. 3) . Heart rate and blood gas did not change during the study period (Table 1) .
Protocol 4: Pulmonary hemodynamic response to norepinephrine infusion. Norepinephrine infusion at 0.5 g/kg/min increased mean PAP by 13% (from 48 Ϯ 5 to 54 Ϯ 5 mm Hg) after 20 min (p Ͻ 0.01; n ϭ 11), and progressively increased left Q p by 61% (from 100 Ϯ 28 to 161 Ϯ 40 mL/min, p Ͻ 0.01; Fig. 4) . During norepinephrine infusion, PVR decreased by 33% (from 0.48 Ϯ 0.1 to 0.32 Ϯ 0.08 mm Hg·min·mL Ϫ1 ; p Ͻ 0.01; Fig. 4 ). Mean AoP increased by 10 Ϯ 1% (from 45 Ϯ 2 to 50 Ϯ 3 mm Hg; p Ͻ 0.05; Table 1 ). Mean PAP, left Q p, and mean AoP progressively returned to baseline value after the end of drug infusion. Mean PVR returned to baseline 30 min after the end of drug infusion. Heart rate and blood gas did not change significantly during the study period (Table 1) .
Protocol 5. Effect of adrenoceptor blockade on the hemodynamic response to norepinephrine. Norepinephrine infusion at 0.5 g·kg Ϫ1 ·min Ϫ1 during yohimbine infusion increased mean PAP by 10% (from 50 Ϯ 3 to 55 Ϯ 3 mm Hg; p Ͻ 0.05; n ϭ 8; Fig. 5 ). Both left Q p and PVR did not change significantly during concomitant norepinephrine and yohimbine infusion (Fig. 5) . Mean AoP, heart rate, and blood gas did not change during the study period (Table 1) .
DISCUSSION
In this in vivo experimental study, we examined the role of the ␣ 2 -adrenoceptors on the pulmonary circulation during fetal life and the mechanisms underlying fetal pulmonary vasodilation induced by norepinephrine. We studied the response to both a selective ␣ 2 -adrenoceptor antagonist and agonist on the basal pulmonary vascular tone and the effect of a selective ␣ 2 -adrenoceptor antagonist on the norepinephrine-induced pulmonary vasodilation in chronically prepared late-gestation fetal lambs. We found that yohimbine (␣ 2 -adrenoceptor antagonist) induces a pulmonary vasoconstriction, whereas UK 14,304 (␣ 2 -adrenoceptor agonist) induces a potent pulmonary vasodilation. NOS inhibition prevents UK 14,304-mediated pulmonary vasodilation. Furthermore, yohimbine abolishes the norepinephrine-mediated pulmonary vasodilation.
This study provides new information regarding the mechanisms that regulate pulmonary vascular tone during fetal life. Low fetal PaO 2 (21, 22) , lack of a gas-liquid interface (1), and production of vasoconstrictor mediators such as leukotrienes (23, 24) and endothelin-1 (25) contribute to maintain high PVR in the fetus. However, endogenous release of NO modulates the vasoconstrictor tone in the late-gestation fetus (4, 5) and mediates pulmonary vasodilation to several physiologic and pharmacologic stimuli such as acetylcholine, shear stress, and oxygen (4, 5, 26, 27) . NO production also contributes to the decrease in PVR at the time of birth (4, 28 -30) . Inhibition of NOS with L-arginine analogs increases basal PVR and selectively blocks endothelium-dependent vasodilation to many stimuli (4). As selective ␣ 2 -adrenoceptor blockade by yohimbine increases PVR, a basal ␣ 2 -adrenoceptor activationinduced vasodilation exists in the fetal lung. The potent pulmonary vasodilation observed with UK 14,304 further indicates that selective activation of ␣ 2 -adrenoceptors decreases PVR. As observed with most pulmonary endotheliumdependent vasodilator stimuli in the fetus (acetylcholine, prostaglandins, shear stress, bradykinin), the pulmonary vascular response to UK 14,304 was transient (2, 3) . The mechanisms opposing prolonged pulmonary vasodilation are uncertain but may include time-dependent decreased ability to sustain production or effectiveness of endogenous vasodilators or enhanced production of vasoconstrictors. Previous in vitro studies clearly showed that ␣ 2 -adrenoceptor activation-induced vasodilation results from NO release (7-9). Our results show- 
47
ing that NO inhibition completely abolishes the UK 14,304-mediated pulmonary vasodilation further support the hypothesis that ␣ 2 -adrenoceptor activation results in pulmonary vasodilation through increased NO release. Taken together, these findings indicate that ␣ 2 -adrenoceptors may modulate basal pulmonary vascular tone in the developing lung and that NO release mediates the ␣ 2 -adrenoceptor activation-induced pulmonary vasodilation.
Endogenous ␣ 2 -adrenoceptor agonists are uncertain, but may include norepinephrine. In vitro studies have reported that relaxant effects of norepinephrine observed in some systemic (15) and pulmonary (16) vessels in newborn animals result from endothelial ␣ 2 -adrenoceptor activation. Our in vivo studies further support the hypothesis that norepinephrine may activate ␣ 2 -adrenoceptors: 1) norepinephrine induces a potent pulmonary vasodilation in fetal lambs (17) ; 2) norepinephrineinduced pulmonary vasodilation is mediated by NO production (17); 3) selective ␣ 2 -adrenoceptor blockade abolishes the pulmonary vasodilator response to norepinephrine; and 4) the ␣ 2 -agonist UK 14,304 mimics the effects of norepinephrine on the pulmonary circulation. High circulating norepinephrine levels are found during fetal life (10, 11) . Thus, the increase in PVR observed in our study during yohimbine infusion may result from inhibition of norepinephrine-induced ␣ 2 -adrenoceptor activation. However, we cannot rule out that Vascular ␣-adrenoceptors are divided into ␣ 1 and ␣ 2 subtypes. In contrast to larger arteries, which generally have only ␣ 1 -adrenoceptors mediating contraction, both ␣ 1 -and ␣ 2 -adrenoceptors are involved in the modulation of tone of the resistance arteries. ␣ 2 -Adrenoceptors can be found both on vascular smooth muscle cells and on the endothelium, where they exert opposing effects on vascular tone. Several lines of evidence suggest that ␣ 2 -adrenoceptors participate in the control of pulmonary vascular tone. Removal of the endothelium causes a shift to the left of the concentration-response curves to norepinephrine and the selective ␣ 2 -adrenoceptor agonist UK 14,304 in canine pulmonary vessels (8) . In that study, norepinephrine and UK 14,304 induced relaxation of precontracted ring vessels in the presence of ␣ 1 -adrenoceptor blockers. These vasorelaxant effects are abolished by ␣ 2 -adrenoceptor antagonists and by endothelium removal (8) . Moreover, ␣ 2 - adrenoceptor agonists mediate relaxation of precontracted porcine pulmonary arteries when endothelium is intact (7) . Inhibition of NOS enhances the contractile response to norepinephrine and UK 14,304 in rabbit isolated pulmonary artery (9) . Our results are in accordance with these in vitro studies. Whereas UK 14,304 decreased PVR, an increase in pulmonary vascular tone was observed with UK 14,304 after L-NA infusion, indicating that NOS inhibition not only abolishes the pulmonary vasodilator effects of ␣ 2 -adrenoceptors agonists but also unmasks their pulmonary vasoconstrictive properties. As ␣ 2 -adrenoceptor agonists induce pulmonary smooth muscle cell contraction (7) (8) (9) , pulmonary vascular response to ␣ 2 -adrenoceptor blockade and activation in our study may result from the balance between activation of ␣ 1 -and ␣ 2 -adrenoceptor-induced vasoconstriction and endothelial ␣ 2 -adrenoceptor-mediated pulmonary vasodilation.
There are four potential limitations to our study. First, the drug infusions (UK 14,304, yohimbine, norepinephrine, L-NA) may have caused changes in ductus arteriosus tone. As ductus arteriosus compression may induce pulmonary vasodilation (3), norepinephrine-and UK 14,304-mediated pulmonary vasodilation may result from ductus arteriosus constriction. However, this hypothesis is unlikely as the pressure gradient between the pulmonary artery and aorta did not change during drug infusion, suggesting a lack of significant effect on basal tone of the ductus arteriosus. Second, we cannot rule out that the changes of PVR observed during UK 14,304 or yohimbine infusion may result, at least in part, from activation or blockade of the presynaptic ␣ 2 -adrenoceptors. Indeed, activation of prejunctional ␣ 2 -adrenoceptors may inhibit stimulation-evoked neurotransmitter release such as norepinephrine from both sympathetic nerves and CNS (31) . Conversely, ␣ 2 -adrenoceptor antagonists may enhance neuronal norepinephrine release (31) . Such changes in sympathetic outflow may modulate pulmonary vascular tone. However, our previous in vivo study does not support this hypothesis as norepinephrine reduces PVR in the fetal lamb (17) . Third, changes in pulmonary vascular tone observed during norepinephrine or yohimbine infusion may result from systemic or centrally mediated reflex events. Indeed, both norepinephrine and yohimbine increase pulmonary and systemic arterial pressure. As an increase in PAP elevates Q p (3), norepinephrine-induced vasodilation may be caused by the mechanical increase in shear stress. Furthermore, shear stress-mediated pulmonary vasodilation is also NO dependent. However, norepinephrine-mediated increase in PAP was lower (mean increase in PAP ϭ 6 mm Hg) than the increase in PAP required to induce pulmonary vasodilation (usually 15 mm Hg) (3). On the other hand, the similar increase in PAP during yohimbine infusion (mean increase in PAP ϭ 7 mm Hg) was associated with decreased Q p. Thus, it is unlikely that the pulmonary vascular effects of norepinephrine or yohimbine may be exclusively related to an increase in PAP. Fourth, at baseline, mean fetal PaO 2 was low in this study. As fetal PaO 2 is a potent modulator of pulmonary vascular tone (32) , low PaO 2 may have increased pulmonary vascular tone or pulmonary vascular reactivity. However, PaO 2 did not change during the experiments. Thus, the pulmonary vascular responses to drug infusion cannot be related to altered fetal PaO 2 .
Moreover, such levels of PaO 2 have been previously reported in fetal lambs (32, 33) . Finally, in our study, basal PVRs were in the same range as those measured in previous studies (17, 32, 33) .
CONCLUSION
In this study, we showed that ␣ 2 -adrenoceptors are involved in the control of basal pulmonary vascular tone and in the pulmonary vasodilator effect of norepinephrine during fetal life. Especially, ␣ 2 -adrenoceptor activation induces a potent NO-dependent pulmonary vasodilation. As a surge of norepinephrine exists at birth, we speculate that norepinephrine and ␣ 2 -adrenoceptor activation may play a significant role in the pulmonary vasodilation at birth, along with other stimuli such as shear stress, increased PaO 2 , tidal ventilation, or bradykinin. The respective role of each factor, which may vary with time (late gestation, birth, immediate postnatal period), remains to be determined.
